On Wednesday, Biocon stock slipped 0.55 per cent to settle at Rs 364.55 apiece on the BSE.

Biocon Limited board approves QIP at ₹387.74 per share, with issue opening on 12 January 2026 and new oncology biosimilars announced.

Pharma stocks rise as Cipla faces supply issues, Zydus gains FDA approval, and Biocon secures funding through a QIP.

This floor price is at a premium to the stock's recent performance. On Monday, shares of Biocon settled 2 per cent lower at Rs 372.05 on the BSE.

Biotech firm Biocon on Thursday said it has raised ₹4,150 crore through a Qualified Institutions Placement (QIP) process. The initiative saw issuance of 1,12,664,585 equity shares of face value ₹5 ...

Indian drugmaker Biocon Ltd drew demand for about four times the shares it offered to institutional investors, with interest ...

Stocks to watch today: The stocks to watch today, 22 January 2026, include Eternal, InterGlobe Aviation, Eternal, Dr Reddy’s Laboratories, Biocon, Hindustan Petroleum Corporation Ltd (HPCL), CESC, ...

Biocon said the proceeds would be primarily used to meet the cash consideration payable to Mylan Inc, now Viatris, for the ...

The board of Biocon has approved the issue of 11.26 crore equity shares of face value of ₹5 each to eligible institutions.

Biocon Ltd. plans to file for regulatory approvals of generic versions of Novo Nordisk A/S's Ozempic and Wegovy in key markets as patents on the blockbuster weight-loss drugs expire next year. The ...

HYDERABAD, Jan 31 (Reuters) - Indian biopharmaceutical firm Biocon (BION.NS), opens new tab is likely to list its key biosimilars business by March 2026 and aims for double-digit share in its core U.S ...

Indian drugmaker Biocon Ltd. drew demand for about four times the shares it offered to institutional investors, with interest largely coming from local mutual funds, according to people familiar with ...